SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors react to the company's recent listing transfer to the Nasdaq Global Select Market and ongoing focus on the commercial rollout of its fibromyalgia treatment, Tonmya. While the community is actively debating the stock's long-term potential and leadership, discussions are dominated by the tension between the product's prescription growth and concerns over share dilution and the company's cash runway.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant downward pressure as investors rotate out of growth stocks, while the community remains divided between those panic-selling and those viewing the recent price drop as a strategic buying opportunity supported by institutional interest from firms like ARK Invest. The ongoing conversation is dominated by frustration over the stock's inability to hold gains, persistent short-selling activity, and the search for a definitive bottom amidst broader market uncertainty.

Trump For President

The $TRUMP crypto token is currently facing intense volatility and skepticism as community members debate its long-term viability, with many investors expressing frustration over recent price declines. The discourse is heavily polarized, fueled by heated political debates and accusations regarding the project's association with broader controversies, while some supporters continue to frame the asset as a speculative opportunity.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing significant post-earnings volatility driven by the surprise announcement of CEO Shantanu Narayen's upcoming departure and ongoing investor skepticism regarding its ability to monetize AI against emerging generative competitors. While the company posted a double beat on revenue and earnings, the community remains sharply divided between those viewing the pullback as a buying opportunity given the firm's strong cash flow and those fearing that AI-driven tools will permanently erode its market share.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp (BULL) is trending as frustrated investors react to a relentless, multi-month slide to new all-time lows, fueling intense debates over persistent share dilution and a perceived lack of transparency from company management. While some retail traders remain fixated on the potential for a short squeeze or a turnaround reminiscent of other fintech stocks, others are aggressively exiting their positions, citing a lack of insider support and a failure to capitalize on market volatility.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending as investors respond to renewed interest in edge AI hardware following industry-wide shifts, alongside anticipation for upcoming corporate presentations and performance benchmarks. Community discussion is sharply divided between bullish expectations regarding potential defense-sector integration and vocal skepticism from traders questioning the company's technical claims and historical transparency.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines ($UMAC) is drawing significant market attention as a key domestic supplier in the defense drone sector, bolstered by its role in the U.S. government's 'Drone Dominance' program and strategic investor ties. Community discussion centers on its potential as a 'picks and shovels' play, with traders highlighting high volatility, rapid production scaling in Florida, and the stock's tendency to react sharply to government contract news and defense industry momentum.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility and massive trading volumes as the escalating conflict in the Middle Eastspecifically surrounding the Strait of Hormuzdrives fears of a historic global supply shock. While the community remains sharply divided, traders are actively debating whether current price levels are sustainable given potential supply-side interventions and conflicting signals regarding future oil tanker safety.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment for SPY is heavily driven by intensifying geopolitical instability in the Middle East and concerns over surging energy costs, with traders closely monitoring the potential impact on global supply chains and inflation. Community discussions are currently polarized, featuring heated debates on the economic consequences of U.S. policy decisions, skepticism toward short-term relief measures like Russian oil purchases, and active speculation on whether upcoming economic data will sustain or break current price trends.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors weigh strong AI-driven order backlogs and record bookings against concerns regarding stretched valuations and potential geopolitical headwinds. While the company remains a critical backbone for advanced chip manufacturing, the community is actively debating whether the stock's parabolic run is sustainable or if a pullback is imminent given broader trade tensions and semiconductor sector rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month High - Time to Buy?

Amicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month High - Still a Buy...

Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 22,500 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 22,500 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average...

Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an...

JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD

JPMorgan Chase & Co. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the...

Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD

Vanguard Group Inc. lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.4% in the third quarter, according to the company in its most recent disclosure with the Securities...

William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD

William Blair Investment Management LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 7.6% during the third quarter, according to the company in its...

Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD

Fox Run Management L.L.C. acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund...

Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD

Primecap Management Co. CA cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 16.1% during the third quarter, according to its most recent 13F filing with the Securities and...

BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market

BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.

Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FOLD News

FOLDAmicus Therapeutics Inc